Biotechnology firm Bharat Biotech International (BBIL) has announced the launch of BioHib, the first indigenously developed and manufactured Haemophilus Influenza Type B (Hib) vaccine in India, and Comvac 4-HB, a tetravalent combination vaccine. "BioHib is a safe and affordable vaccine that offers complete protection against Hib Infection", a company release said. "BioHib is a conjugate vaccine that has proven its safety and efficacy in multi-centric clinical trials". While other Indian manufacturers had imported conjugation and manufacturing technologies from Europe and the USA, the scientific manufacturing and product development teams at Bharat Biotech have developed all processes required to manufacture Bio Hib in-house, the company said. The company had made huge investments over the past four years into its Research and Development capabilities and its manufacturing facilities to develop and manufacture BioHib vaccine. The Comvac4-HB and BioHib enable the deployment of a combination pentavalent vaccine in a single injection, the release said.